Leukocyte response to thymoglobulin or atgam for induction immunosuppression in a randomized, double-blind clinical trial in renal transplant recipients

Transplant Proc. 1999 May;31(3B Suppl):16S-18S. doi: 10.1016/s0041-1345(99)00096-2.

Authors

D C Brennan¹, K Flavin, J A Lowell, T K Howard, S Shenoy, S Burgess, S Dolan, J M Kano, M Mahon, M A Schnitzler, R Woodward, W Irish, V Ramachamdra, G G Singer

Affiliation

¹ Department of Internal Medicine, Washington University School of Medicine, St. Louis, Missouri, USA. dbrennan@msnotes.wustl.edu

PMID: 10330962
DOI: 10.1016/s0041-1345(99)00096-2

No abstract available

Publication types

Clinical Trial
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

MeSH terms

Antilymphocyte Serum / therapeutic use*
Double-Blind Method
Graft Rejection / prevention & control*
Humans
Immunosuppressive Agents / therapeutic use*
Kidney Transplantation*
Lymphocyte Count
T-Lymphocyte Subsets / drug effects

Substances

Antilymphocyte Serum
Immunosuppressive Agents